MedTrace Logo

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

NCT07535359 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.

Conditions

  • SCLC
  • Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Ifinatamab Deruxtecan

12 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)

Sponsors & Collaborators

Principal Investigators

  • Global Oncology Medical Affairs · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07535359 on ClinicalTrials.gov